Ibrutinib added to Standard-of-Care Therapy improves PFS by 50% for Older Patients with Newly Diagnosed Mantle Cell Lymphoma
The SHINE study is the first international phase III trial to demonstrate a positive impact of ibrutinib combined with standard-of-care treatment in Mantle Cell Lymphoma. The progression-free survival is substantially longer than the common treatment options used today.
Få tilgang til artikkelen
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in